Antibody Therapy

1. Front Matter

   Pages i-xiv

   PDF

2. The Clinical Translation of Intravenous Immunoglobulin from Substitution to Immunomodulation

   • Paul Imbach

   Pages 1-11

3. Update of Substitutive and Immunomodulatory Antibodies/Drugs Indications

   1. Front Matter

      Pages 13-13

      PDF

   2. From Immune Substitution to Immuno-modulation

      • Volker Wahn

      Pages 15-22

   3. Manual of Primary and Secondary Immunodeficiencies

      • Paul Imbach, Volker Wahn

      Pages 23-33

   4. Manual of Intravenous and Subcutaneous IgG Indications in Autoimmune Diseases

      • Paul Imbach

      Pages 35-60

   5. Anti-D: A Type of IVIg

      • Ramsha Khan, Alan H. Lazarus

      Pages 61-71

   6. Mechanisms of Action and Immunomodulation by IVIg

      • Alan H. Lazarus

      Pages 73-83

   7. Immunomodulatory Drugs and Monoclonal Antibodies

      • Howard A. Liebman

      Pages 85-100

   8. Use of Intravenous Immunoglobulin in Neurology

      • Marinos C. Dalakas

      Pages 101-109

   9. Use of Intravenous Immunoglobulin in Dermatology

      • Jochen H. O. Hoffmann, Alexander H. Enk

      Pages 111-118

4. Basics of IgG Concentrates

   1. Front Matter

      Pages 119-119

      PDF

   2. Historical Aspects of Polyclonal IgG Preparations

      • Volker Wahn, Peter Späth

      Pages 121-132

   3. Basics of Immunoglobulins as Effector Molecules and Drugs

      • Tchavdar L. Vassilev, Victor Kostov, Stephan von Gunten, Anastas D. Pashov

      Pages 133-150

   4. Essentials of the Production of Safe and Efficacious State-of-the-Art Polyclonal IgG Concentrates

      • Peter J. Späth

      Pages 151-173

   5. Current IgG Products and Future Perspectives

      • Peter J. Späth

      Pages 175-202

5. Immune Thrombocytopenia: The First Immunomodulatory IgG Treatment

   1. Front Matter

      Pages 203-203

      PDF

   2. Updates in Immune Thrombocytopenia: Terminology, Immunomodulation and Platelet Stimulation, and Clinical Guidelines and Management

      • Cindy Neunert

      Pages 205-212

   3. Health-Related Quality of Life in Patients with Immune Thrombocytopenia

      • Robert J. Klaassen, Nancy L. Young

      Pages 213-222

   4. ITP in Childhood: Predictors of Disease Duration

      • Carolyn M. Bennett

      Pages 223-239

This practical manual, written by well-known experts, reviews current indications for the use of IgG concentrates and some other modern immunomodulators and provides fundamental information on present-day immunomodulation in patients (and mice). The book opens by tracing the transition from IgG substitution to IgG immunomodulation and providing expert updates on immunomodulatory indications in autoimmune and inflammatory disorders, including hematologic, neurologic, dermatologic, and other diseases. Basic aspects of IgG concentrates, including methods of production, safety, currently available products, and mechanisms of action, are then discussed. An entire chapter is devoted to the different aspects of immunomodulatory IgG treatment in the bleeding disorder immune thrombocytopenia (ITP). Finally, the transition from polyclonal to monoclonal antibody (mAb) treatment is addressed in detail, covering mAb development, methods, mechanisms of action, adverse effects, and more. Particular attention is paid to the example of anti-CD20 (B-cell) antibody.

• Immunoglobulin G Concentrate
• Immune Thrombocytopenia
• Immunomodulation
• Autoimmune Disorders
• Mangement of Immune Thrombocytopenia

“The book strives to provide basic information on current immunomodulation primarily covering clinical aspects with a few preclinical studies. … Overall, this is an excellent book on the subject that is delivered in a practical manual format.” (Ravi Salgia, Doody's Book Reviews, March, 22 , 2019)

​

• Department of Pediatrics, Medical Faculty of the University of Basel, Basel, Switzerland

  Paul Imbach

Paul (August) Imbach is a highly respected pediatric oncologist-hematologist who has developed worldwide clinical research on the indications for intravenous immunoglobulin. Dr. Imbach graduated in Medicine in 1972. He went on to structure the Swiss Pediatric Oncology Group (SPOG) and in 1978 performed the first autologous stem cell transplantation in Switzerland. He discovered the immunomodulatory effects of human immunoglobulin G concentrate (IVIG) in childhood immune thrombocytopenia (as reported in Lancet in 1981). In 1990, Dr. Imbach began working at the University Children’s Hospital Basel, where he started stem cell transplantation in children and was appointed Head of Pediatric Oncology-Hematology. He was subsequently elected as full professor and also as Dean of Education introducing a thorough curriculum reform of the medical faculty at the University of Basel. In parallel to his other activities, he co-founded the International Cooperative ITP Study ICIS group, which now has more than 90 centers worldwide. He has served as president of medical societies and foundations, is a member of various medical editorial boards, and has published over 300 peer-reviewed articles as well as the textbook Pediatric Oncology – A Comprehensive Guide (3rd edition 2014) in German and English. In 2015 he was awarded the Guido Fanconi Prize, the highest award of the Swiss Society of Pediatrics.

Policies and ethics